Study of GRAd-COV2 for the Prevention of COVID-19 in Adults

NCT ID: NCT04791423

Last Updated: 2023-03-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 10300 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-03-15
• Study Completion Date: 2022-05-13

Brief Summary

Multicenter Study assessing the safety, efficacy, and immunogenicity of the candidate vaccine GRAd-COV2, compared to placebo, for the prevention of COVID-19. Participants will be adults ≥ 18 years of age who are healthy or have medically stable chronic diseases and are at increased risk for SARS-CoV-2 acquisition and COVID-19. In the phase II part approximately 900 participants will be randomized in a 1:1:1 ratio to receive i) 2 repeated (21 days apart) intramuscular (IM) doses of GRAd-COV2 at 1x10^11 viral particle (vp) (n = approximately 300 subjects) ii) 1 single IM dose of GRAd-COV2 at 2x10^11 vp plus 1 dose of placebo after 21 days (n= approximately 300 subject) or 2 doses of placebo (n = approximately 300 subjects) on day 1 and day 22. There will be 3 strata for randomization: ≥ 65 years, < 65 years and categorized to be at increased risk ("at risk") for the complications of COVID-19, and < 65 years "not at risk". Risk will be defined referring to the study participants' relevant past and current medical history. An independent Data Safety Monitoring Board will provide oversight, to ensure safe and ethical conduct of the Study; a Steering Committee will revise safety data (collected for 900 participants 1 week after dosing) and immunogenicity data (collected for 450 participants 5 weeks after the first dosing) generated in phase II part. Jointly DSMB and SC will recommend the expansion to phase III and the best regimen to be used.

Conditions

Covid19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Single dose of GRAd-COV2

1 single IM dose of GRAd-COV2 2 x 10\^11 vp plus 1 dose of saline placebo after 21 days

Group Type: EXPERIMENTAL

GRAd-COV2

Intervention Type: BIOLOGICAL

GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues

Double dose of GRAd-COV2

2 repeated (21 days apart) IM dose of GRAd-COV2 1 x 10\^11

Group Type: EXPERIMENTAL

GRAd-COV2

Intervention Type: BIOLOGICAL

GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues

Placebo

Two doses of saline placebo on day 1 and day 22

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Saline solution

Interventions

GRAd-COV2

GRAd-COV2 is a replication-defective gorilla adenoviral vector (GRAd) encoding the SARS-CoV-2 surface glycoprotein (S, Spike) antigen under the control of CMV immediate early promoter. The encoded Spike antigen is stabilized in pre-fusion conformation by introducing 2 proline residues

Intervention Type: BIOLOGICAL

Placebo

Saline solution

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Adult female and male, ≥ 18 years of age at the time of consent

2. Medically stable such that, according to the judgment of the investigator, hospitalization within the study period is not anticipated and the participant appears likely to be able to remain on study through the end of protocol-specified follow-up. A stable medical condition is defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 3 months prior to enrollment

3. Able to understand and comply with study requirements/procedures based on the assessment of the investigator

4. Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

5. Female participants, (a) Women of childbearing potential must: Have a negative pregnancy test on the day of screening and on Day 1; use one highly effective form of birth control for at least 28 days prior to Day 1 and agree to continue using one highly effective form of birth control through 60 days following administration of study intervention.

6. Capable of giving signed informed consent.

Exclusion Criteria

1. History of allergy to any component of the vaccine

2. History of Guillain-Barré syndrome or any other demyelinating condition

3. Significant infection or other acute illness, including fever > 37.3 °C on the day prior to or day of randomization

4. History of laboratory-confirmed SARS-CoV-2 infection

5. Any confirmed or suspected immunosuppressive or immunodeficient state, including asplenia (only for phase II)

6. Recurrent severe infections and use of immunosuppressant medication within the past 6 months

7. History of primary malignancy except for: (a) Malignancy with low potential risk for recurrence after curative treatment (for example, history of childhood leukaemia) or metastasis (for example, indolent prostate cancer) in the opinion of the site investigator. (b) Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease (c) Adequately treated uterine cervical carcinoma in situ without evidence of disease (d) Localized prostate cancer (only for phase II)

8. Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or vene puncture

9. Severe and/or uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease, liver disease, renal disease, endocrine disorder, and neurological illness, as judged by the Investigator (mild/moderate well-controlled comorbidities are allowed) (only for phase II)

10. Any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data

11. Receipt of, or planned receipt of investigational or licensed products indicated for the treatment or prevention of SARS-CoV-2 or COVID-19

12. Receipt of any vaccine (licensed or investigational) other than licensed influenza vaccines within 30 days prior to and after administration of study intervention

13. Receipt of immunoglobulins and/or any blood products within 3 months prior to administration of study intervention or expected receipt during the period of study follow-up

14. Involvement in the planning and/or conduct of this study (applies to both Sponsor staff and/or staff at the study site)

15. For women only - currently pregnant (confirmed with positive pregnancy test) or breast-feeding

16. Has donated ≥ 450 mL of blood products within 30 days prior to randomization or expects to donate blood within 90 days of administration of study intervention.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS

NETWORK

Sponsor Role: collaborator

ReiThera Srl

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Simone Lanini, Consultant

Role: PRINCIPAL_INVESTIGATOR

Istituto per le Malattie Infettive Lazzaro Spallanzani IRCCS

Locations

Ospedale Vittorio Emanuele Ii

Bisceglie, Barletta- Andria-Trani, Italy

Istituto per le Malattie Infettive Lazzaro Spallanzani IRCCS

Roma, RM, Italy

Azienda Ospedaliera San Giuseppe Moscati

Avellino, , Italy

A.O. Sant'Anna E San Sebastiano Caserta

Caserta, , Italy

Asst Di Cremona

Cremona, , Italy

Azienda Ospedaliero-Universitaria Di Ferrara

Ferrara, , Italy

Ao Ospedali Riuniti - Foggia

Foggia, , Italy

E.O. Ospedali Galliera

Genova, , Italy

Presidio Ospedaliero Nord-Ospedale Santa Maria Goretti Latina

Latina, , Italy

Fondaz.Irccs Ca' Granda - Ospedale Maggiore Policlinico

Milan, , Italy

Asst Fatebenefratelli Sacco

Milan, , Italy

Ospedale S.Gerardo - Monza

Monza, , Italy

Azienda Ospedaliera Dei Colli - P Cotugno

Napoli, , Italy

Azienda Ospedaliera Universitaria Della Universita' Vanvitelli I Di Napoli

Napoli, , Italy

Az.Osp.Univ.P.Giaccone

Palermo, , Italy

Azienda Ospedaliero-Universitaria Di Parma

Parma, , Italy

Policlinico S. Matteo - Pavia

Pavia, , Italy

Azienda Usl Di Piacenza

Piacenza, , Italy

Azienda Ospedaliero-Universitaria Pisana

Pisa, , Italy

Azienda Ospedaliera Policlinico Umberto I

Roma, , Italy

Policlinico A. Gemelli E C.I.C.- Policlinico Universitario A. Gemelli

Roma, , Italy

Ospedale Amedeo Di Savoia

Torino, , Italy

Azienda Sanitaria Universitaria Integrata Di Trieste

Trieste, , Italy

Asst Dei Sette Laghi

Varese, , Italy

Ospedale Unico Del Vercellese - Ospedale Sant'Andrea

Vercelli, , Italy

Centro Ricerche Cliniche Di Verona Srl

Verona, , Italy

Countries

Italy

References

Capone S, Fusco FM, Milleri S, Borre S, Carbonara S, Lo Caputo S, Leone S, Gori G, Maggi P, Cascio A, Lichtner M, Cauda R, Dal Zoppo S, Cossu MV, Gori A, Roda S, Confalonieri P, Bonora S, Missale G, Codeluppi M, Mezzaroma I, Capici S, Pontali E, Libanore M, Diani A, Lanini S, Battella S, Contino AM, Piano Mortari E, Genova F, Parente G, Dragonetti R, Colloca S, Visani L, Iannacone C, Carsetti R, Folgori A, Camerini R; COVITAR study group. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial. Cell Rep Med. 2023 Jun 20;4(6):101084. doi: 10.1016/j.xcrm.2023.101084. Epub 2023 May 29.

Reference Type: DERIVED

PMID: 37315558 (View on PubMed)

Other Identifiers

RT-CoV-2_01

Identifier Type: -

Identifier Source: org_study_id